» Articles » PMID: 37101812

Bioinspired Lipid Nanocarriers for RNA Delivery

Overview
Specialty Biochemistry
Date 2023 Apr 27
PMID 37101812
Authors
Affiliations
Soon will be listed here.
Abstract

RNA therapy is a disruptive technology comprising a rapidly expanding category of drugs. Further translation of RNA therapies to the clinic will improve the treatment of many diseases and help enable personalized medicine. However, in vivo delivery of RNA remains challenging due to the lack of appropriate delivery tools. Current state-of-the-art carriers such as ionizable lipid nanoparticles still face significant challenges, including frequent localization to clearance-associated organs and limited (1-2%) endosomal escape. Thus, delivery vehicles must be improved to further unlock the full potential of RNA therapeutics. An emerging strategy is to modify existing or new lipid nanocarriers by incorporating bioinspired design principles. This method generally aims to improve tissue targeting, cellular uptake, and endosomal escape, addressing some of the critical issues facing the field. In this review, we introduce the different strategies for creating bioinspired lipid-based RNA carriers and discuss the potential implications of each strategy based on reported findings. These strategies include incorporating naturally derived lipids into existing nanocarriers and mimicking bioderived molecules, viruses, and exosomes. We evaluate each strategy based on the critical factors required for delivery vehicles to succeed. Finally, we point to areas of research that should be furthered to enable the more successful rational design of lipid nanocarriers for RNA delivery.

Citing Articles

Rational design and modular synthesis of biodegradable ionizable lipids via the Passerini reaction for mRNA delivery.

Xu Y, Gong F, Golubovic A, Strilchuk A, Chen J, Zhou M Proc Natl Acad Sci U S A. 2025; 122(5):e2409572122.

PMID: 39883839 PMC: 11804478. DOI: 10.1073/pnas.2409572122.


Extracellular vesicle mimetics as delivery vehicles for oligonucleotide-based therapeutics and plasmid DNA.

Oshchepkova A, Chernikov I, Miroshnichenko S, Patutina O, Markov O, Savin I Front Bioeng Biotechnol. 2024; 12:1437817.

PMID: 39493304 PMC: 11528538. DOI: 10.3389/fbioe.2024.1437817.


The multifaceted roles of circular RNAs in cancer hallmarks: From mechanisms to clinical implications.

Kundu I, Varshney S, Karnati S, Naidu S Mol Ther Nucleic Acids. 2024; 35(3):102286.

PMID: 39188305 PMC: 11345389. DOI: 10.1016/j.omtn.2024.102286.


Synergistic vesicle-vector systems for targeted delivery.

Marquez C, Oh C, Ahn G, Shin W, Kim Y, Ahn J J Nanobiotechnology. 2024; 22(1):6.

PMID: 38167116 PMC: 10763086. DOI: 10.1186/s12951-023-02275-6.

References
1.
Du F, Zhou J, Gong R, Huang X, Pansuria M, Virtue A . Endothelial progenitor cells in atherosclerosis. Front Biosci (Landmark Ed). 2012; 17(6):2327-49. PMC: 3368338. DOI: 10.2741/4055. View

2.
Cui S, Wang Y, Gong Y, Lin X, Zhao Y, Zhi D . Correlation of the cytotoxic effects of cationic lipids with their headgroups. Toxicol Res (Camb). 2018; 7(3):473-479. PMC: 6062336. DOI: 10.1039/c8tx00005k. View

3.
Huckriede A, de Jonge J, Holtrop M, Wilschut J . Cellular delivery of siRNA mediated by fusion-active virosomes. J Liposome Res. 2007; 17(1):39-47. DOI: 10.1080/08982100601186516. View

4.
Akinc A, Querbes W, De S, Qin J, Frank-Kamenetsky M, Narayanannair Jayaprakash K . Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther. 2010; 18(7):1357-64. PMC: 2911264. DOI: 10.1038/mt.2010.85. View

5.
Murphy D, de Jong O, Evers M, Nurazizah M, Schiffelers R, Vader P . Natural or Synthetic RNA Delivery: A Stoichiometric Comparison of Extracellular Vesicles and Synthetic Nanoparticles. Nano Lett. 2021; 21(4):1888-1895. PMC: 8023702. DOI: 10.1021/acs.nanolett.1c00094. View